NCT06579573 is a Phase 3 clinical trial of Cenobamate in Epilepsy, Generalized, sponsored by Ono Pharmaceutical Co., Ltd..

Who is sponsoring NCT06579573?

NCT06579573 is sponsored by Ono Pharmaceutical Co., Ltd..

What drugs are being tested in NCT06579573?

Interventions in NCT06579573: Cenobamate.

What condition does NCT06579573 study?

NCT06579573 studies Epilepsy, Generalized.

Is NCT06579573 still recruiting?

NCT06579573 is currently recruiting now. Last updated 17 June 2025.

Last reviewed 2025-06-17 · How we verify

NCT06579573

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.

Recruiting now Phase 3 Last updated 17 June 2025

What this trial tests

Phase 3 trial testing Cenobamate in Epilepsy, Generalized in 15 participants. Currently enrolling.

Timeline

12 July 2022

Primary endpoint
31 January 2027

31 January 2027

Quick facts

Lead sponsor	Ono Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	12 July 2022
Primary completion	31 January 2027
Estimated completion	31 January 2027
Sites	25 locations across Japan

Drugs / interventions tested

Cenobamate (CENOBAMATE) — full drug profile →

Conditions studied

Epilepsy, Generalized — all drugs for Epilepsy, Generalized →

Sponsor

Ono Pharmaceutical Co., Ltd.

Who can join

12 and older, any sex, with Epilepsy, Generalized. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy and safety of ONO-2017 in combination with antiepileptics in Japanese epileptic patients with generalized tonic-clonic seizures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Epilepsy therapy beyond neurons: Unveiling astrocytes as cellular targets.
Chen Y, Hu J, Zhang Y, Peng L, et al · · 2026 · cited 9× · PMID 39819836 · DOI 10.4103/nrr.nrr-d-24-01035

Verify or expand the search:

Other trials of Cenobamate

Trials testing the same drug.

NCT06453213 — Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy · Phase 4 · active not recruiting
NCT06590896 — Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures · Phase 2 · recruiting
NCT05572255 — A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Admini · Phase 1 · completed
NCT04791553 — Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment · Phase 1 · completed
NCT03678753 — Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures · Phase 3 · completed

Other recruiting trials for Epilepsy, Generalized

Currently open trials in the same condition.

NCT06769659 — A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Abse · Phase 2 · recruiting
NCT06399952 — Baker Gordon Syndrome Natural History Study · recruiting

Other Ono Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07169708 — A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable · not yet recruiting
NCT06936943 — ONO-4538 Study in Patients With Richter's Transformation · Phase 2 · recruiting
NCT06948448 — A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an · Phase 2 · recruiting
NCT07198087 — A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impa · Phase 1 · active not recruiting
NCT06803823 — A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06579573 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ono Pharmaceutical Co., Ltd.
Last refreshed: 17 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06579573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing